TRML241220C20000
- 3.89
- -4.40-53.08%
Tourmaline Bio Newsroom
Leerink Partners Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Express News | Cantor Fitzgerald Reiterates Overweight on Tourmaline Bio, Maintains $25 Price Target
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Strategic Developments in Tourmaline Bio's Cardiovascular Programs Drive Buy Rating
Tourmaline Bio Unveils Clinical Progress and New Indication
Tourmaline Bio Highlights Cardiovascular Inflammation Focus And Announces Key Clinical And Strategic Updates At Investor Day; Phase 2 TRANQUILITY Trial Surpasses Enrollment Target, With 143 Total Patients Enrolled
Tourmaline Bio Surpasses Enrollment Target in Phase 2 TRANQUILITY Trial and Expands Cardiovascular Focus
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
UBS Raises Price Target on Tourmaline Bio to CA$73 From CA$70, Maintains Neutral Rating
Tourmaline Bio Price Target Announced at $50.00/Share by BMO Capital
Tourmaline Bio Initiated at Outperform by BMO Capital
Tourmaline Bio Analyst Ratings
BMO Capital Initiates Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $50
Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Tourmaline Bio (TRML)
Tourmaline Bio, Inc. Announces Virtual Investor Day to Discuss Development of Pacibekitug on December 10, 2024
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $49
Express News | Tourmaline Bio Inc Files for Mixed Shelf of up to $350 Mln - SEC Filing
Talaris Therapeutics GAAP EPS of -$0.78 Beats by $0.05
Tourmaline Bio | 10-Q: Q3 2024 Earnings Report